Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data ...

PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological ...

A new discovery offers hope for Huntington’s disease. This discovery provides hope that a DNA repair process may help slow or ...

The expansion of CAG trinucleotide repeats located in the coding sequence (CDS) of various human genes is associated with the development of neurodegenerative disorders (NDs), including Huntington’s ...

Scheduled Feeding improved sleep/wake rhythms in the Fmr1 KO mutants.

HD is an autosomal dominant genetic disorder affecting five to ten in 100,000 people and caused by a mutation of the huntingtin (HTT) gene, which results in extended CAG trinucleotide repeats.

Melissa Beiner, M.D., SCA Clinical Development Lead at Biohaven, commented, Our NDA filing is the culmination of over 8 years of clinical research a ...

The behavior of a person's genes doesn't just depend on the genes' DNA sequence - it's also affected by so-called epigenetic factors. Changes in these factors can play a critical role in disease ...